🔎 Trials Near Me

Hjem › Burkitts lymfom › Illinois › Chicago

Burkitts lymfom kliniske forsøg i Chicago, IL

14 studier for Burkitts lymfom søger deltagere på steder i og omkring Chicago (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
366 Days – 46 Years · Alle køn · Opdateret 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

RekruttererFase 3
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • og 1 flere
Alder 18 til 39 · Alle køn · Opdateret 2. okt. 2026 · NCT03150693

Blinatumomab Consolidation in Real World

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
  • Northwestern University, Chicago
  • The University of Chicago, Chicago
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

RekruttererFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RekruttererFase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 1 til 30 · Alle køn · Opdateret 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RekruttererFase 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

RekruttererFase 2
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Alder 7 til 25 · Alle køn · Opdateret 19. aug. 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

RekruttererFase 1/2
  • Research Site, Chicago
Alder 12 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

RekruttererFase 1/2
  • Research Site, Chicago
Alder 12 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

RekruttererFase 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 til 54 · Alle køn · Opdateret 17. mar. 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

RekruttererFase 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Alder 18 og opefter · Alle køn · Opdateret 4. nov. 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

RekruttererFase 1/2
  • University of Chicago, Chicago
Alder 15 til 50 · Alle køn · Opdateret 9. sep. 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Rekrutterer
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Alder 18 til 50 · Alle køn · Opdateret 19. jun. 2025 · NCT06785324

Burkitts lymfom forsøg i andre byer

Andre studier i Chicago

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.